Stockscreener 앱 받기
12.99
0.07%
0.010
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - Investing.com Canada
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics stock falls after pricing $175 million public offering By Investing.com - Investing.com Canada
Fulcrum Therapeutics prices $175 million public offering By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Prices $175 Million Stock Offering - marketscreener.com
What is HC Wainwright's Forecast for FULC FY2028 Earnings? - MarketBeat
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Fulcrum Therapeutics announces pricing of upsized $175.0 million public offering of common stock and pre-funded warrants - marketscreener.com
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation - Nasdaq
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.8% on Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView — Track All Markets
RBC Capital Maintains Fulcrum Therapeutics (FULC) Sector Perform Recommendation - Nasdaq
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering - GuruFocus
Fulcrum stock drops after announcing $150 million public offering By Investing.com - Investing.com Australia
Fulcrum Therapeutics launches $150 million common stock offering - Investing.com
Fulcrum stock drops after announcing $150 million public offering - Investing.com
Fulcrum Therapeutics launches $150 million common stock offering By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Launches $150 Million Common Stock Offering - marketscreener.com
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - The Manila Times
Fulcrum Therapeutics (Nasdaq: FULC) starts proposed $150.0M raise, plus $22.5M option - Stock Titan
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data - Investing.com Canada
Fulcrum Therapeutics’ Promising Surge: Analyzing Recent Progress - StocksToTrade
The growth track for Fulcrum Therapeutics Inc (FULC) has changed recently - Setenews
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - inkl
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Piper Sandler Raises Price Target and Reiterates Overweight Rati - GuruFocus
Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Fulcrum Therapeutics jumps after trial data of blood disorder drug - TradingView — Track All Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
FULC: Cantor Fitzgerald Raises Price Target to $24, Maintains Ov - GuruFocus
FULC: RBC Capital Raises Price Target to $10, Maintains Sector P - GuruFocus
Is Fulcrum Therapeutics Stock Set to Skyrocket? - timothysykes.com
Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data - Investing.com UK
Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright - Investing.com Canada
Fulcrum Therapeutics stock price target raised to $23 from $16 at Piper Sandler - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
0.56%
1.23%
자본화:
|
볼륨(24시간):